Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Intranasal FluGen vaccine offers protection in human challenge study

The company is increasing its focus on flu vaccines after beginning work on a COVID-19 vaccine known as CoroFlu. 

By Brian Buntz | August 3, 2021

FluGenMadison, Wis.–based FluGen has announced that its Bris2007 M2SR flu vaccine candidate demonstrated protection against a multi-seasonal, seven-year drifted influenza strain in a Phase 2 study.

Some 54% of M2SR vaccine recipients were infected after exposure to a flu strain. Conversely, 71% of placebo recipients were infected, indicating that the vaccine was 24% effective against the strain.

The results, which were published in the Journal of Infectious Diseases, mark the first time a vaccine demonstrated the ability to protect against a highly drifted influenza A (H3N2) flu virus in a human challenge study, according to FluGen.

The study indicates that the vaccine triggers a broad immune response. Conversely, traditional flu vaccines offer strain-specific protection and struggle to protect against the H3N2 strain, which has driven an increasing proportion of flu cases in recent years.

In the challenge study, investigators randomized adults aged 18 to 55 to receive a single dose of either vaccine or placebo. Four weeks later, they were exposed to the H3N2 virus (A/Belgium/4217/2015) influenza strain. FluGen’s intranasal vaccine is based on the A/Brisbane/10/2007 strain.

A single dose of the vaccine induced neutralizing antibodies in 48% of recipients. Some 27% of recipients induced such antibodies in response to the challenge strain.


Filed Under: clinical trials, Drug Discovery, Infectious Disease, Uncategorized
Tagged With: flu, FluGen, influenza
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
Vial of Steroid injection with a syringe on black table and stainless steel background.
The true cost of steroid-toxicity 
3D illustration of Palm painful - skeleton x-ray, medical concept.
Q&A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE